Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma
Authors Li G, Xu H, Ji J, Yang F, Gao B
Received 19 September 2015
Accepted for publication 14 January 2016
Published 1 March 2016 Volume 2016:9 Pages 1085—1093
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jia Fan
Peer reviewer comments 2
Editor who approved publication: Professor Daniele Santini
Guang-Jun Li,1 Hong-Wei Xu,1 Juan-Juan Ji,2 Fang Yang,2 Bao-Qin Gao1
1First Department of General Surgery, 2Department of Gastroenterology, First Affiliated Hospital of Xin-Xiang Medical University, Henan, People’s Republic of China
Background: Inflammation and immunity have an important role in the development of cancer. The lymphocyte-to-monocyte ratio (LMR) has been shown to be of prognostic value in several malignant forms. The purpose of this study was to analyze the prognostic significance of preoperative LMR in post-curative resection of pancreatic adenocarcinoma.
Methods: A total of 144 patients with primary pancreatic adenocarcinoma who underwent curative operation were enrolled in this retrospective study. The correlation between preoperative LMR and survival was analyzed using Kaplan–Meier curves and multivariate Cox regression analyses.
Results: In the univariate analysis, an elevated preoperative LMR was significantly associated with an increased overall survival (OS) (19 months vs 12 months, P=0.000), and this result remained significant in the multivariate analysis (hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.085–0.252; P=0.000). Furthermore, patients with high LMR also had higher median recurrence-free survival (RFS) than patients with low LMR in univariate (18 months vs 10 months, P=0.000) and multivariate analyses (HR: 0.148; 95% CI: 0.085–0.252; P=0.000). Subgroup analyses showed that both patients with stage III cancer and patients with stage I+II cancer can obtain OS and RFS benefits from high LMR.
Conclusion: LMR can be considered as an independent prognostic biomarker for operable pancreatic adenocarcinoma.
Keywords: lymphocyte to monocyte ratio, survival, pancreatic adenocarcinoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]